All In Biotech

Drug Trial Radar · NCT07596485

RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, and PRELIminary EFficacy of Percutaneous Injection of RP-008 Followed by Daily Oral Varenicline in Patients With Trigeminal Neuralgia (The RELIEF Study)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
Kriya Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate. The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.

Conditions

  • Trigeminal Neuralgia

Interventions

  • RP-008Genetic

    RP-008 will be administered as a single percutaneous injection to the trigeminal ganglion.

  • Varenicline tartrateDrug

    Varenicline tartrate will be administered as a daily oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal electrocardiograms (ECGs), and suicidal ideationTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Sherbrooke

    Sherbrooke, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.